Patent Settlements Are ‘Critically Necessary’ As AAM Calculates $423bn Savings Since 2013
Joint AAM-IQVIA Report Analyzed 84 Molecules That Entered The Market Early
The US healthcare system saved billions by allowing early market entry for generic and biosimilar medicines through patent settlements. However, long-winded litigations with an expensive price tag and the Senate’s reintroduced pay-for-delay bill are set to make the situation even more dire.
